GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avecho Biotechnology Ltd (ASX:AVE) » Definitions » EV-to-Revenue

Avecho Biotechnology (ASX:AVE) EV-to-Revenue : 8.84 (As of May. 29, 2024)


View and export this data going back to 1993. Start your Free Trial

What is Avecho Biotechnology EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Avecho Biotechnology's enterprise value is A$4.18 Mil. Avecho Biotechnology's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.47 Mil. Therefore, Avecho Biotechnology's EV-to-Revenue for today is 8.84.

The historical rank and industry rank for Avecho Biotechnology's EV-to-Revenue or its related term are showing as below:

ASX:AVE' s EV-to-Revenue Range Over the Past 10 Years
Min: -3.51   Med: 5.97   Max: 85.55
Current: 8.84

During the past 13 years, the highest EV-to-Revenue of Avecho Biotechnology was 85.55. The lowest was -3.51. And the median was 5.97.

ASX:AVE's EV-to-Revenue is ranked worse than
62.93% of 1036 companies
in the Biotechnology industry
Industry Median: 8.17 vs ASX:AVE: 8.84

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-29), Avecho Biotechnology's stock price is A$0.003. Avecho Biotechnology's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00. Therefore, Avecho Biotechnology's PS Ratio for today is .


Avecho Biotechnology EV-to-Revenue Historical Data

The historical data trend for Avecho Biotechnology's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avecho Biotechnology EV-to-Revenue Chart

Avecho Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.75 116.00 30.69 21.85 12.16

Avecho Biotechnology Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.69 - 21.85 - 12.16

Competitive Comparison of Avecho Biotechnology's EV-to-Revenue

For the Biotechnology subindustry, Avecho Biotechnology's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avecho Biotechnology's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avecho Biotechnology's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Avecho Biotechnology's EV-to-Revenue falls into.



Avecho Biotechnology EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Avecho Biotechnology's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=4.179/0.473
=8.84

Avecho Biotechnology's current Enterprise Value is A$4.18 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Avecho Biotechnology's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avecho Biotechnology  (ASX:AVE) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Avecho Biotechnology's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.003/0
=

Avecho Biotechnology's share price for today is A$0.003.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avecho Biotechnology EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Avecho Biotechnology's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Avecho Biotechnology (ASX:AVE) Business Description

Traded in Other Exchanges
Address
Unit A8, 2A Westall Road, Clayton, Melbourne, VIC, AUS, 3168
Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sale, and licensing of products incorporating its patented platform technology TPM, for the pharmaceutical, skincare and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.

Avecho Biotechnology (ASX:AVE) Headlines

No Headlines